转移性肾细胞癌前瞻性2期临床试验中主动监测时间缩短的分子遗传决定因素
该研究对唯一现代评估转移性肾细胞癌主动监测(AS)的临床试验中前瞻性收集的标本进行探索性分析,采用全外显子组和RNA测序识别与AS持续时间(TAS)相关的生物标志物。TP53或SMARCA4肿瘤抑制基因突变的患者TAS较短(7.5 vs 14.2个月;log-rank p=0.004),两基因模型在多变量分析中独立预测TAS(HR 3.30,95%CI 1.07-10.18;p=0.038)。
要点
- TP53或SMARCA4突变的mRCC患者AS持续时间较短(7.5 vs 14.2个月,p=0.004)。
- 两基因模型在多变量分析中独立预测AS持续时间(HR 3.30,95%CI 1.07-10.18;p=0.038)。
- 作者认为若经验证,该两基因模型可帮助分层mRCC患者并识别不适合AS者。
核心结论
- 对肾细胞癌生物学的深入了解可改善AS的患者选择。
- 若经验证,该两基因模型可帮助分层mRCC患者并识别不适合AS的患者。
- 携带TP53或SMARCA4突变的患者可能不是AS的良好候选者。
研究设计与样本
- 对唯一现代评估mRCC中AS的临床试验中前瞻性收集的标本进行探索性分析。
- 对同意患者行全外显子组和RNA测序以识别与TAS相关的推定生物标志物。
- 采用log-rank检验和多变量Cox比例风险模型进行分析。
主要发现
- TP53或SMARCA4肿瘤抑制基因突变的患者TAS较短(7.5 vs 14.2个月;log-rank p=0.004)。
- 这些患者临床上有侵袭性疾病特征,但两基因模型在多变量分析中独立预测TAS(HR 3.30,95%CI 1.07-10.18;p=0.038)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Active surveillance (AS) may be used in the management of metastatic renal cell carcinoma (mRCC), but consensus regarding its application is lacking. We report an exploratory analysis of prospectively collected specimens prespecified in the only modern clinical trial evaluating AS in mRCC. Whole-exome and RNA sequencing were performed for patients providing consent to identify putative biomarkers associated with time on AS (TAS), the primary endpoint. Log-rank tests and multivariable Cox proportional-hazards models were used for analyses. Patients with mutations in either TP53 or SMARCA4 tumor suppressor genes had shorter TAS (7.5 vs 14.2 mo; log-rank p = 0.004). While these patients exhibited features of aggressive disease clinically, the two-gene model was independently predictive in multivariable analyses (hazard ratio 3.30, 95% confidence interval 1.07-10.18; p = 0.038). In conclusion, insight into the underlying RCC biology improves patient selection for AS. If validated, this two-gene model could help in stratifying patients with mRCC and identifying those who are poor candidates for AS. PATIENT SUMMARY: In this study, we analyzed tumors from patients with metastatic kidney cancer enrolled in a clinical trial of imaging surveillance. We found that tumors with mutations in either the TP53 or SMARCA4 gene progressed faster than tumors without these mutations. Thus, patients harboring mutations in these genes may not be good candidates for AS.
引用
- Reig Torras O, Mishra A, Christie A, et al. Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. Eur Urol. 2021. PMID: 34980496. doi:10.1016/j.eururo.2021.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。